SOCRA CCRP — Certified Clinical Research Professional — Questions and Answers

Question 1: Which phase of clinical trials is the first to involve human participants?

Phase IV
Phase II
Phase III
Phase I (Correct answer)

Correct answer: Phase I

Phase I is the first phase that involves human participants, typically testing safety, tolerability, and pharmacokinetics in a small group of healthy volunteers.

Question 2: Under 21 CFR 812.150, an investigator must report an unanticipated adverse device effect to the sponsor and IRB within:

5 working days
30 calendar days
15 calendar days
10 working days (Correct answer)

Correct answer: 10 working days

Investigators must submit UADE reports to the sponsor and reviewing IRB as soon as possible but no later than 10 working days.

Question 3: Which of the following BEST describes a 'waiver' in the context of protocol deviations?

Prior written approval from the IRB or sponsor to deviate from a specific protocol requirement (Correct answer)
A post-hoc justification for a deviation already committed
Sponsor permission granted after the fact to excuse a missed procedure
An FDA exemption from IND requirements for a specific site

Correct answer: Prior written approval from the IRB or sponsor to deviate from a specific protocol requirement

A protocol waiver is prospective written authorization from the sponsor and/or IRB to deviate from a specific protocol requirement under defined circumstances, obtained before the deviation occurs.

Question 4: A subject enrolled in a clinical trial misses a required blood draw by 5 days due to a personal emergency. How should the Clinical Research Coordinator (CRC) handle this?

Reschedule the draw without documenting the variance
Obtain a retroactive protocol amendment from the IRB
Document the missed visit as a protocol deviation and notify the PI and sponsor (Correct answer)
Remove the subject from the study immediately

Correct answer: Document the missed visit as a protocol deviation and notify the PI and sponsor

Missed assessments outside the protocol-specified window must be documented as protocol deviations and reported per the sponsor's and IRB's procedures.

Question 5: Which FDA form is used by sponsors to submit expedited IND safety reports (individual case safety reports) to the agency?

FDA Form 1572 (Statement of Investigator)
FDA Form 2253 (Promotional Materials)
FDA Form 356h (NDA Application)
FDA Form 3500A (MedWatch) (Correct answer)

Correct answer: FDA Form 3500A (MedWatch)

FDA Form 3500A (MedWatch) is the mandatory reporting form used for expedited IND safety reports submitted to the FDA.

Question 6: In adverse event causality assessment, what does a 'probable' relationship between an investigational product and an adverse event indicate?

The investigational product is the sole confirmed cause of the adverse event
No plausible biological relationship exists between the drug and the event
The causal relationship cannot be evaluated due to insufficient information
A reasonable causal relationship exists and alternative explanations are unlikely, with the event improving on dechallenge (Correct answer)

Correct answer: A reasonable causal relationship exists and alternative explanations are unlikely, with the event improving on dechallenge

'Probable' causality means there is a plausible time relationship, alternative explanations are unlikely, and the event typically improves on dechallenge (withdrawal of the drug). It suggests a likely connection but does not reach the certainty of 'definite,' which also requires positive rechallenge or definitive confirmation.

Question 7: What does the FDA's 'Disqualification of Clinical Investigators' process under 21 CFR 312.70 require before a final order of disqualification is issued?

Sponsor certification that the investigator can no longer receive investigational drugs
IRB vote to revoke the investigator's research privileges
Automatic disqualification upon receipt of a BIMO inspection finding
Opportunity for the investigator to respond in writing and request a regulatory hearing (Correct answer)

Correct answer: Opportunity for the investigator to respond in writing and request a regulatory hearing

Before disqualification, FDA must provide the investigator written notice and an opportunity to respond in writing and, if requested, a regulatory hearing under 21 CFR Part 16.

Question 8: What is 21CFR50.25 Subpart B?

Exemptions of Informed Consent
Documentation of Informed Consent
Elements of Informed Consent (Correct answer)
Documentation of Emergency Use of Experimental Treatments

Correct answer: Elements of Informed Consent

21 CFR 50.25, found within Subpart B, precisely outlines the 'Elements of Informed Consent' that must be provided to prospective research subjects. This section details the essential information, such as the study's purpose, risks, benefits, and alternatives, that must be communicated to ensure a subject can make an informed decision about participation. It serves as a cornerstone for ethical human subjects research.

Question 9: What is a protocol deviation versus a protocol violation?

A deviation is more serious
A violation only occurs when the sponsor makes changes
A deviation is any departure from the protocol; a violation is a deviation that affects safety or data integrity (Correct answer)
They are the same thing

Correct answer: A deviation is any departure from the protocol; a violation is a deviation that affects safety or data integrity

A deviation is any unplanned departure from the protocol, while a violation is a significant deviation that may affect participant safety, rights, or data integrity.

Question 10: How often must a continuing IEC review occur at minimum under ICH GCP guidelines?

At least once per year (Correct answer)
Every 6 months
Only when protocol amendments are submitted
Every 3 months

Correct answer: At least once per year

ICH E6 requires that the IEC conduct continuing review of each ongoing trial at least once per year.

Question 11: An Institutional Review Board (IRB) or Independent Ethics Committee (IEC) has several key responsibilities in overseeing clinical research. Which of the following is a primary responsibility of the IRB/IEC?

Ensuring the scientific validity and statistical power of the study design.
Safeguarding the rights, safety, and well-being of all trial participants. (Correct answer)
Auditing the financial agreements between the sponsor and the investigator.
Verifying the accuracy of the clinical data collected at the research site.

Correct answer: Safeguarding the rights, safety, and well-being of all trial participants.

The primary and overarching responsibility of an IRB/IEC is to protect the rights, safety, and well-being of human subjects involved in a clinical trial. While they review aspects of the study like the protocol and consent form, their core mission is the protection of participants.

Question 12: When the sponsor and the IRB disagree about whether an investigational device study is significant risk (SR) or non-significant risk (NSR), who makes the final determination?

The sponsor
The FDA (Correct answer)
The IRB
The principal investigator

Correct answer: The FDA

The sponsor makes the first SR/NSR assessment and the IRB reviews it. If there is a dispute or question, the FDA makes the final determination.

Question 13: What does 'source data' refer to under ICH E6(R2) GCP guidelines?

All information in original records and certified copies of findings, observations, or other activities (Correct answer)
Only data entered into the sponsor's database
Data reviewed and approved by the IRB only
Summarized data submitted in the final study report

Correct answer: All information in original records and certified copies of findings, observations, or other activities

ICH E6(R2) defines source data as all information in original records and certified copies used to reconstruct and evaluate a clinical trial.

Question 14: What is the purpose of FDA Form 3455?

Document overhead costs
Disclose investigators' financial interests that could affect objectivity (Correct answer)
Report participant compensation
Calculate study budget

Correct answer: Disclose investigators' financial interests that could affect objectivity

Form 3455 requires disclosure of financial interests that could be affected by study outcome.

Question 15: What is a Development Safety Update Report (DSUR)?

A daily safety summary
A report only when SAEs occur
An annual report providing comprehensive safety analysis during drug development (Correct answer)
A post-marketing report

Correct answer: An annual report providing comprehensive safety analysis during drug development

A DSUR is an annual report providing comprehensive safety analysis of information collected during the reporting period.

Question 16: The responsibility for ensuring that the investigator understands a clinical trial lies with which individual/or organization?

Sponsor (Correct answer)
FDA
Coordinator
IRB

Correct answer: Sponsor

The sponsor of a clinical trial holds the ultimate responsibility for ensuring that the investigator understands the clinical trial protocol and their obligations. This includes providing comprehensive training, clear study documents, and ongoing support to the investigator. The sponsor's oversight is crucial for maintaining the integrity of the study and protecting the rights and safety of subjects.

Question 17: Which monitoring approach involves a targeted review of a predefined percentage of source data rather than reviewing every data point?

100% SDV monitoring
Remote data lock verification
Triggered on-site monitoring
Statistical sampling-based SDV (Correct answer)

Correct answer: Statistical sampling-based SDV

Statistical sampling-based SDV reviews a defined subset of data points, often guided by risk assessment, rather than verifying every CRF entry against source documents.

Question 18: What is the difference between an adverse event (AE) and an adverse drug reaction (ADR)?

AEs are reported to the FDA while ADRs are only reported to the IRB
ADRs only occur in Phase I trials
AEs are more severe than ADRs
An ADR implies a causal relationship to the drug, while an AE does not require one (Correct answer)

Correct answer: An ADR implies a causal relationship to the drug, while an AE does not require one

An AE is any undesirable experience regardless of causality; an ADR (also called a suspected adverse reaction) implies that there is at least a reasonable possibility that the drug caused the event.

Question 19: How does ICH-GCP define IRB/IEC responsibilities?

Only handles finances
Oversees manufacturing
No defined role
Protect rights, safety, and well-being by reviewing protocols, consent forms, and investigator qualifications (Correct answer)

Correct answer: Protect rights, safety, and well-being by reviewing protocols, consent forms, and investigator qualifications

Section 3: the IRB/IEC safeguards rights, safety, and well-being through independent review and approval.

Question 20: What is the Trial Master File (TMF)?

A document maintained only by regulatory authorities
A collection of essential documents that individually and collectively permit evaluation of the conduct of a trial (Correct answer)
A financial accounting document for study costs
A database of all adverse events reported during the trial

Correct answer: A collection of essential documents that individually and collectively permit evaluation of the conduct of a trial

The TMF is the complete collection of essential documents that allows reconstruction of the trial, demonstrating compliance with GCP and regulatory requirements.

Question 21: Which of the following best describes the ethical obligation of 'non-abandonment' in clinical research?

Sponsors must not terminate a trial without regulatory approval
Researchers must ensure participants receive appropriate care if they withdraw or the trial ends (Correct answer)
IRBs must continue reviewing a study until all follow-up data is collected
Investigators must not withdraw a participant's data once collected

Correct answer: Researchers must ensure participants receive appropriate care if they withdraw or the trial ends

Non-abandonment requires that researchers ensure participants have access to continued care or appropriate referrals if they withdraw from a study or if the study is terminated, protecting their wellbeing beyond the trial itself.

Question 22: According to GCP guidelines, what is the correct way to correct an error in a paper source document?

Cross out the entire entry with multiple lines and rewrite the full entry on the next available line
Erase the error completely and write the correct information in the same space
Apply correction fluid over the error, write the correct information above it, and initial the change
Draw a single line through the error, write the correction nearby, and add initials, date, and reason for change (Correct answer)

Correct answer: Draw a single line through the error, write the correction nearby, and add initials, date, and reason for change

GCP requires that the original entry remain legible after any correction. A single line through the error, followed by the corrected value, the corrector's initials, the date, and the reason for the change preserves the audit trail and demonstrates transparency.

Question 23: Which of the following is a primary responsibility of the Principal Investigator regarding adverse event management?

To determine the final causality of an event independently of the sponsor's medical monitor.
To report all Serious Adverse Events (SAEs) directly to the FDA within 24 hours.
To report only unexpected and related adverse events to the Institutional Review Board (IRB).
To document all adverse events and report them to the sponsor according to the protocol-specified timelines and procedures. (Correct answer)

Correct answer: To document all adverse events and report them to the sponsor according to the protocol-specified timelines and procedures.

The Principal Investigator is responsible for ensuring all adverse events (AEs) are properly documented in the source records and reported to the sponsor. The specific timelines and methods for reporting both serious and non-serious AEs are dictated by the clinical trial protocol. Investigators report SAEs to the sponsor, not directly to the FDA.

Question 24: Which of the following is considered a 'vulnerable population' requiring additional protections in research?

Economically disadvantaged individuals who may be unduly influenced by payment (Correct answer)
Healthy adult volunteers aged 25-40
Participants in a fitness study
Faculty members at research universities

Correct answer: Economically disadvantaged individuals who may be unduly influenced by payment

Economically disadvantaged individuals may be vulnerable to undue influence from financial incentives, requiring additional safeguards in research participation.

Question 25: What is a regulatory binder?

Only IRB approvals
A financial records folder
Only the protocol
A comprehensive collection of all regulatory and essential documents required for study conduct at the site (Correct answer)

Correct answer: A comprehensive collection of all regulatory and essential documents required for study conduct at the site

The regulatory binder contains all essential documents including IRB approvals, protocol, consent forms, delegation log, and correspondence.

Question 26: What are IP labeling requirements?

Must identify product as investigational, include protocol number, sponsor info, storage conditions per 21 CFR 312.6 (Correct answer)
Commercial labeling sufficient
No labeling needed
Only drug name

Correct answer: Must identify product as investigational, include protocol number, sponsor info, storage conditions per 21 CFR 312.6

Labels must include the investigational caution statement, protocol number, sponsor name, storage conditions, and lot number.

Question 27: According to ICH E6(R2), what is the required timeframe for an investigator to report an unexpected serious adverse event (SAE) to the sponsor?

Within 5 working days, as defined by local regulations
Within 7 calendar days of becoming aware of the event
Within 24 hours of becoming aware of the event, followed by a written report within 8 days (Correct answer)
Within 48 hours, with a follow-up report within 15 days

Correct answer: Within 24 hours of becoming aware of the event, followed by a written report within 8 days

ICH E6(R2) Section 4.11 requires that all serious adverse events be reported immediately to the sponsor, except those identified in the protocol as not requiring immediate reporting. The standard expectation is immediate (within 24 hours) notification with a detailed written follow-up within 8 days.

Question 28: A clinical trial is designed to test a new medication for a common chronic condition. To ensure rapid enrollment, the research team decides to recruit participants exclusively from a low-income clinic that serves a predominantly minority population. Which ethical principle is most directly compromised by this recruitment strategy?

Justice (Correct answer)
Respect for Persons
Beneficence
Non-maleficence

Correct answer: Justice

The principle of Justice requires the fair and equitable distribution of the burdens and benefits of research. Recruiting exclusively from a vulnerable or conveniently available population, which may not fully enjoy the benefits of the research, violates the principle of fair subject selection.

Question 29: What is the FDA form 3455?

Declaration of Conflict of Interest
Certification - Disclosure of Conflict of Interest
Disclosure - Financial Interests and Agreements of Clinical Investigators (Correct answer)
Certification - Financial Interests and Arrangements of Clinical Investigators

Correct answer: Disclosure - Financial Interests and Agreements of Clinical Investigators

FDA Form 3455 is specifically titled 'Disclosure - Financial Interests and Agreements of Clinical Investigators.' This form is used by clinical investigators to disclose any financial interests or arrangements they or their immediate family members have with the sponsor of a covered clinical study. This disclosure is crucial for identifying and managing potential conflicts of interest that could bias study results.

Question 30: Which of the following is a required safeguard when prisoners are enrolled in research?

At least one IRB member must be a prisoner or prisoner representative (Correct answer)
All prisoner research must receive OHRP approval before the IRB reviews it
Prisoners must make up the majority of IRB membership
The warden must co-sign the consent form

Correct answer: At least one IRB member must be a prisoner or prisoner representative

45 CFR 46 Subpart C requires that a majority of the IRB members involved in reviewing prisoner research have no association with the prison, and at least one member must be a prisoner or prisoner representative.

Question 31: Source data in a clinical trial, as defined by ICH GCP, must be ALCOA-C. What does the 'C' in this acronym stand for?

Confidential
Complete (Correct answer)
Contemporaneous
Certified

Correct answer: Complete

The acronym ALCOA-C (or ALCOA+) refers to the standards for high-quality data. It stands for Attributable, Legible, Contemporaneous, Original, Accurate, and Complete. 'Complete' means that the data includes all pertinent observations for that subject, without missing information.

Question 32: What is the role of pharmacovigilance during a clinical trial?

Collect, assess, and report safety data throughout the trial lifecycle (Correct answer)
Manage the trial budget
Recruit participants
Manufacture the investigational product

Correct answer: Collect, assess, and report safety data throughout the trial lifecycle

Pharmacovigilance is responsible for systematic collection, detection, assessment, monitoring, and prevention of adverse effects.

Question 33: Which subpart of 45 CFR 46 gives additional protections for children involved as research subjects?

Subpart A
Subpart C
Subpart D (Correct answer)
Subpart B

Correct answer: Subpart D

Subpart D covers children; Subpart B covers pregnant women, fetuses, and neonates, and Subpart C covers prisoners.

Question 34: Which Belmont Report principle most directly requires fair and equitable selection of research subjects?

Justice (Correct answer)
Autonomy
Beneficence
Respect for persons

Correct answer: Justice

The principle of justice concerns the fair distribution of research burdens and benefits, which is applied through equitable subject selection.

Question 35: What is the purpose of Form FDA 1572?

Statement of Investigator committing to comply with IND regulations (Correct answer)
Financial disclosure by clinical investigators
IRB registration with FDA
Sponsor's annual IND progress report

Correct answer: Statement of Investigator committing to comply with IND regulations

Form FDA 1572 is the Statement of Investigator, in which the investigator agrees to conduct the study under 21 CFR 312 requirements.

Question 36: Which statement best describes an investigator's responsibility for investigational product accountability at the site?

Accountability may be delegated to the pharmacy without any investigator oversight
Product accountability records are kept exclusively by the sponsor's CRO
The investigator must maintain records of product receipt, use, return, and destruction (Correct answer)
Only unused product needs to be accounted for at the end of the trial

Correct answer: The investigator must maintain records of product receipt, use, return, and destruction

ICH E6 section 4.6 requires the investigator to maintain accurate records of the investigational product at the site throughout the trial.

Question 37: Which FDA regulation requires sponsors to monitor clinical investigations and defines the CRO's ability to assume sponsor responsibilities?

21 CFR 312.68 and 312.70
21 CFR 56.115 and 56.109
21 CFR 312.50 and 312.52 (Correct answer)
21 CFR 50.20 and 50.25

Correct answer: 21 CFR 312.50 and 312.52

21 CFR 312.50 establishes general sponsor responsibilities including monitoring, while 312.52 governs the transfer of sponsor obligations to CROs.

Question 38: What are IRB requirements under FDA regulations?

Only pediatric
IRBs are optional
IRBs must review all human subjects research with specific membership, procedural, and record-keeping requirements per 21 CFR 56 (Correct answer)
Only Phase III

Correct answer: IRBs must review all human subjects research with specific membership, procedural, and record-keeping requirements per 21 CFR 56

Under 21 CFR 56, IRBs must review clinical investigations with diverse membership and specific procedures.

Question 39: At a clinical site, all protocol deviations are being captured in a deviation log. According to GCP, which of the following is MOST important about this log?

It should be maintained by the sponsor rather than the site
It should only include deviations identified by the sponsor's CRA during monitoring visits
It should be complete, contemporaneous, and accessible for review by monitors, auditors, and inspectors (Correct answer)
It only needs to include deviations that were reported to the FDA

Correct answer: It should be complete, contemporaneous, and accessible for review by monitors, auditors, and inspectors

GCP requires that deviation logs be complete, maintained in real time, and available for review by all appropriate oversight parties including monitors, auditors, and regulatory inspectors.

Question 40: How do major protocol deviations usually affect a subject's inclusion in statistical analysis populations?

The subject may be excluded from the per-protocol population but stays in the intent-to-treat population (Correct answer)
The deviation has no effect on any analysis population
The subject is removed from every analysis population
The subject's data are deleted from the database

Correct answer: The subject may be excluded from the per-protocol population but stays in the intent-to-treat population

Important deviations often exclude subjects from the per-protocol set, while ITT keeps all randomized subjects.

Question 41: What is the purpose of a close-out visit?

To negotiate the next trial
To ensure all obligations are complete, documents archived, and drug accountability finalized (Correct answer)
To start enrolling
To train new staff

Correct answer: To ensure all obligations are complete, documents archived, and drug accountability finalized

A close-out visit ensures queries are resolved, documents complete, IP accounted for, and the site understands ongoing obligations.

Question 42: What is data integrity?

The degree to which data is complete, consistent, accurate, and reliable throughout its lifecycle (Correct answer)
Data storage capacity
Only electronic data
Only matters for the final report

Correct answer: The degree to which data is complete, consistent, accurate, and reliable throughout its lifecycle

Data integrity encompasses completeness, consistency, accuracy, and reliability throughout the data lifecycle.

Question 43: What is the significance of FDA Form 3674?

Manufacturing certification
Investigator qualifications
Certifies that trial information has been or will be submitted to ClinicalTrials.gov (Correct answer)
Certifies drug safety

Correct answer: Certifies that trial information has been or will be submitted to ClinicalTrials.gov

Form 3674 certifies compliance with ClinicalTrials.gov requirements as mandated by FDAAA Section 801.

Question 44: In international multicenter trials, which document harmonizes GCP standards across the US, EU, and Japan to ensure consistent participant protections?

FDA Guidance for Industry 21 CFR Part 50
ICH E6(R2) Guideline for Good Clinical Practice (Correct answer)
The CIOMS International Ethical Guidelines
The Belmont Report

Correct answer: ICH E6(R2) Guideline for Good Clinical Practice

ICH E6(R2) is the internationally harmonized GCP guideline developed through the International Council for Harmonisation to align standards across major regulatory regions.

Question 45: What is 21 CFR Part 11?

Trial registration
Drug labeling requirements
Requirements for electronic records and electronic signatures to be trustworthy and equivalent to paper (Correct answer)
AE classification

Correct answer: Requirements for electronic records and electronic signatures to be trustworthy and equivalent to paper

21 CFR Part 11 establishes criteria for electronic records and signatures to be trustworthy and equivalent to paper.

Question 46: Under 21 CFR 312.305, expanded access (compassionate use) for an individual patient in an emergency requires which of the following before treatment may begin?

Full IND submission and 30-day FDA review period
A pre-IND meeting with FDA and sponsor agreement
IRB approval, sponsor consent, and a signed patient waiver
FDA verbal authorization, with a written protocol submission within 15 days (Correct answer)

Correct answer: FDA verbal authorization, with a written protocol submission within 15 days

For emergency individual patient expanded access, FDA may authorize treatment verbally or via other rapid means; the IND or protocol may be submitted within 15 working days after authorization.

Question 47: An investigator must report a serious adverse event (SAE) to the sponsor within what timeframe per ICH E6 GCP guidelines?

Within 24 hours of awareness (Correct answer)
Within 7 calendar days of awareness
Within 15 calendar days of occurrence
Immediately upon occurrence

Correct answer: Within 24 hours of awareness

ICH E6 requires investigators to report SAEs to the sponsor promptly, typically within 24 hours of first awareness of the event.

Question 48: Which scenario would most likely require the IRB to suspend or terminate a study under 21 CFR 56.113?

Unexpected serious harm is occurring to subjects (Correct answer)
A subject misses a study visit
A CRC leaves the research team
The investigator submits a late protocol deviation report

Correct answer: Unexpected serious harm is occurring to subjects

The IRB has authority to suspend or terminate research when unexpected serious harm to subjects is identified, as required under 21 CFR 56.113.

Question 49: A source document location log is used at a clinical trial site primarily to:

Record adverse events in chronological order
Track which subjects have completed all study visits
Identify where source data for each data point can be found across multiple source document types (Correct answer)
Log the names of all personnel who have accessed the investigator site file

Correct answer: Identify where source data for each data point can be found across multiple source document types

A source document location log maps each data element or field to its specific source document, enabling efficient SDV and audit trail reconstruction.

Question 50: Who is responsible for maintaining the Investigator Site File (ISF)?

The principal investigator and site staff (Correct answer)
The FDA district office
The sponsor's CRA
The IRB

Correct answer: The principal investigator and site staff

The principal investigator and site study team are responsible for maintaining the ISF (also called the Investigator's File or Regulatory Binder) at the investigative site.

Question 51: When should unblinding occur?

Every visit
Only in medical emergencies when treatment knowledge is essential for patient care (Correct answer)
Sponsor can unblind anytime
Whenever participant requests

Correct answer: Only in medical emergencies when treatment knowledge is essential for patient care

Unblinding should only occur in medical emergencies when knowing treatment is essential for medical management.

Question 52: A sponsor grants a prospective waiver allowing a site to enroll a subject who fails an inclusion criterion. How does FDA view this?

It is a protocol change that needs IRB approval before it is implemented (Correct answer)
It is permitted if the subject signs an additional consent form
It is acceptable if the medical monitor documents approval
It needs only to be reported in the final study report

Correct answer: It is a protocol change that needs IRB approval before it is implemented

FDA treats prospective, intentional deviations such as eligibility waivers as protocol changes needing IRB review and approval before they are implemented.

Question 53: A subject with fluctuating decision-making capacity signs consent during a lucid interval. What is the most appropriate next step?

Proceed without further action since consent was obtained
Obtain only LAR consent and discard the subject's consent
Exclude the subject from the study
Obtain concurrent LAR consent and reassess capacity regularly (Correct answer)

Correct answer: Obtain concurrent LAR consent and reassess capacity regularly

Best practice for subjects with fluctuating capacity is to obtain both LAR consent and subject assent, with ongoing capacity reassessment.

Question 54: What are the phases of drug development from preclinical through post-marketing?

Phase I, II, III only
Preclinical, Phase I, Phase II, Phase III, and Phase IV (post-marketing) (Correct answer)
Phase I through Phase V
Discovery, Testing, Approval

Correct answer: Preclinical, Phase I, Phase II, Phase III, and Phase IV (post-marketing)

Drug development progresses from preclinical testing through Phase I (safety), Phase II (efficacy/dosing), Phase III (confirmatory), review, and Phase IV (post-marketing).

Question 55: IND safety reports (15-day expedited reports) submitted to the FDA must also be forwarded to:

The NIH clinical trials registry
The IRB that approved the sponsor's master protocol only
All participating investigators under the IND (Correct answer)
Only the sponsor's legal department

Correct answer: All participating investigators under the IND

Under 21 CFR 312.32, sponsors must promptly distribute IND safety reports (SUSARs/expedited reports) to all investigators participating under the IND.

Question 56: Under 21 CFR 312.32, non-fatal, non-life-threatening unexpected SUSARs must be reported to the FDA within:

7 calendar days
60 calendar days
30 calendar days
15 calendar days (Correct answer)

Correct answer: 15 calendar days

Non-fatal, non-life-threatening unexpected SUSARs must be reported to the FDA within 15 calendar days of the sponsor's first awareness.

Question 57: A Humanitarian Use Device (HUD) is intended to treat or diagnose a disease or condition that affects how many people in the United States per year?

No more than 8,000 (Correct answer)
No more than 200,000
No more than 4,000
No more than 50,000

Correct answer: No more than 8,000

The 21st Century Cures Act raised the HUD threshold from 4,000 to no more than 8,000 individuals in the U.S. per year. HUDs are approved through a Humanitarian Device Exemption (HDE).

Question 58: Which condition must be met for an IRB to approve a waiver of informed consent for research under 45 CFR 46.116(f)?

The research must involve only healthy volunteers
The research could not practicably be carried out without the waiver (Correct answer)
The study must be double-blinded
The sponsor must request the waiver in writing

Correct answer: The research could not practicably be carried out without the waiver

One key criterion for a consent waiver is that the research could not practicably be carried out without the waiver of informed consent.

Question 59: Under ICH E6(R2) GCP, which party bears ultimate responsibility for the conduct and integrity of a clinical trial?

The principal investigator
The contract research organization (CRO)
The IRB/IEC
The sponsor (Correct answer)

Correct answer: The sponsor

Under ICH E6(R2), the sponsor bears ultimate responsibility for the trial, although they may delegate duties to a CRO.

Question 60: Which principle underpins the requirement that researchers must report unanticipated problems involving risks to subjects or others to the IRB?

Beneficence and non-maleficence — protecting participants from harm (Correct answer)
Respect for persons — honoring participant autonomy
Beneficence — the duty to maximize benefit
Justice — fair distribution of research benefits

Correct answer: Beneficence and non-maleficence — protecting participants from harm

Reporting unanticipated problems protects participants from harm, reflecting the combined principles of beneficence and non-maleficence.

Question 61: What is risk-based monitoring (RBM) per ICH E6(R2)?

Monitoring only high-enrollment sites
Eliminating on-site visits
A monitoring approach focusing resources on critical data and processes based on risks (Correct answer)
Only for Phase III

Correct answer: A monitoring approach focusing resources on critical data and processes based on risks

RBM directs monitoring toward the most important aspects based on risk assessment, combining on-site and centralized techniques.

Question 62: A clinical research coordinator performs a routine inventory of the investigational product and discovers a discrepancy between the dispensing log and the physical count. What is the MOST appropriate first step?

Order a new shipment from the sponsor to replace the missing product.
Assume a documentation error occurred and adjust the dispensing log to match the physical count.
Immediately quarantine the remaining stock, document the discrepancy, and notify the Principal Investigator and sponsor. (Correct answer)
Inform the monitor at the next scheduled visit.

Correct answer: Immediately quarantine the remaining stock, document the discrepancy, and notify the Principal Investigator and sponsor.

According to GCP principles, any discrepancy in investigational product accountability must be addressed immediately to ensure patient safety and data integrity. The first step is to secure the remaining product (quarantine), thoroughly document the finding, and promptly report it to the Principal Investigator and the sponsor. This allows for a timely investigation into the cause of the discrepancy.

Question 63: The 'Enduring' attribute added to ALCOA+ means that source data must be:

Reviewed by the sponsor at least annually
Submitted to the FDA within a defined timeframe
Backed up daily to a cloud server
Stored in a way that it remains readable and accessible for the required retention period (Correct answer)

Correct answer: Stored in a way that it remains readable and accessible for the required retention period

Enduring means data must be stored in durable formats that remain legible and retrievable throughout the required retention period.

Question 64: An investigator fails to report a serious adverse event to the sponsor within the ICH GCP-required timeframe. This is considered a:

Significant protocol deviation with potential regulatory and ethical consequences (Correct answer)
Minor protocol deviation that can be noted in the study close-out report
Non-issue if the event resolved without sequelae
Administrative error correctable by a sponsor waiver

Correct answer: Significant protocol deviation with potential regulatory and ethical consequences

Failure to report SAEs within the required timelines is a significant GCP deviation that can compromise subject safety and data integrity, with regulatory consequences.

Question 65: When is direct data entry (DDE) into an EDC system considered acceptable as source data?

Only when paper source documents have been lost
Only for non-safety data points
When the site has documented procedures establishing the EDC as the source and no prior paper record was created (Correct answer)
When the sponsor provides written approval for each individual entry

Correct answer: When the site has documented procedures establishing the EDC as the source and no prior paper record was created

DDE into EDC is acceptable as source when the site's SOPs designate the EDC as the source and data is entered contemporaneously without a prior paper record.

Question 66: What are IP storage requirements?

Any room temperature
Optional
Per label requirements and sponsor instructions, with temperature monitoring and restricted access (Correct answer)
Only sponsor stores IP

Correct answer: Per label requirements and sponsor instructions, with temperature monitoring and restricted access

IP must be stored per label, IB, and sponsor instructions with continuous monitoring and restricted access.

Question 67: Under the FDA Safety Reporting Final Rule (2010), which of the following is NOT required to be reported as an IND safety report?

Clinically important increased rate of serious suspected adverse reactions
Findings from animal or in vitro studies suggesting significant risk to humans
Expected adverse events that occur within the frequency predicted by the protocol (Correct answer)
Unexpected fatal SUSARs

Correct answer: Expected adverse events that occur within the frequency predicted by the protocol

Expected adverse events that fall within the anticipated frequency do not meet the threshold for IND safety reporting; only unexpected or newly identified safety signals require expedited reporting.

Question 68: How long must investigators typically retain essential documents, including source documents, after a clinical trial is completed under FDA regulations?

5 years after the last subject's last visit
2 years after the date of marketing approval or discontinuation of the IND (Correct answer)
10 years after the trial ends regardless of approval status
1 year after study completion

Correct answer: 2 years after the date of marketing approval or discontinuation of the IND

Under 21 CFR 312.62, investigators must retain records for two years after marketing approval or, if approval is not sought, two years after discontinuation of the IND.

Question 69: How should consent be conducted in emergencies?

Never needed
Obtain from LAR if available; if not, 21 CFR 50.23 or 50.24 provisions may apply with documentation and reporting (Correct answer)
Same as regular consent
Verbal only

Correct answer: Obtain from LAR if available; if not, 21 CFR 50.23 or 50.24 provisions may apply with documentation and reporting

Seek consent from participant or LAR. If impossible, 21 CFR 50.23 (individual use) or 50.24 (research protocol) may apply.

Question 70: What are data retention requirements?

Destroy after study
Only electronic data
Retained for specified periods (typically 2+ years after marketing approval) per ICH, FDA, and local requirements (Correct answer)
At investigator's discretion

Correct answer: Retained for specified periods (typically 2+ years after marketing approval) per ICH, FDA, and local requirements

Records must be retained per regulations: FDA requires 2 years after marketing approval; actual retention is often 15-25 years.

Question 71: What is the purpose of an audit trail in electronic data systems?

To monitor recruitment rates
To generate statistical reports
To track the study budget
To provide a secure, computer-generated record of all data changes with timestamps (Correct answer)

Correct answer: To provide a secure, computer-generated record of all data changes with timestamps

An audit trail is a secure, computer-generated, time-stamped electronic record that allows reconstruction of events related to data creation, modification, and deletion.

Question 72: If a subject's primary source data exists in hospital records held by an institution, what is the investigator's responsibility?

The investigator must transfer all hospital records to the sponsor at study close-out
The investigator must copy all hospital records into the investigator site file
The investigator must ensure the sponsor's monitor can access those records for SDV, as permitted by applicable regulations (Correct answer)
The investigator has no responsibility for records held by the institution

Correct answer: The investigator must ensure the sponsor's monitor can access those records for SDV, as permitted by applicable regulations

The investigator is responsible for ensuring monitors can access source data needed for verification, within the constraints of privacy and confidentiality agreements.

Question 73: A clinical investigator holds equity in the company sponsoring the trial they are conducting. This situation is best described as:

A violation of GCP that automatically disqualifies the investigator
An acceptable arrangement provided it is disclosed to the sponsor
A minor administrative issue requiring no action
A financial conflict of interest that must be disclosed to the IRB and managed appropriately (Correct answer)

Correct answer: A financial conflict of interest that must be disclosed to the IRB and managed appropriately

Financial interests in a sponsor company represent a conflict of interest that must be disclosed and managed to protect research integrity and participant safety.

Question 74: What is the difference between 21 CFR 50 and 21 CFR 56?

Both are post-marketing
Same thing
Part 50 governs informed consent; Part 56 governs IRBs (Correct answer)
Part 50 is manufacturing, 56 is labeling

Correct answer: Part 50 governs informed consent; Part 56 governs IRBs

Part 50 covers informed consent requirements; Part 56 covers IRB composition, operations, and responsibilities.

Question 75: In emergency research under 21 CFR 50.24, what must occur within how many days after enrollment without consent?

The IRB must be notified within 3 working days
The subject or LAR must be asked for consent as soon as feasible (Correct answer)
The community must be notified within 30 days of study closure
The subject or LAR must be informed within 5 business days

Correct answer: The subject or LAR must be asked for consent as soon as feasible

Under 21 CFR 50.24, consent from the subject or LAR must be sought as soon as feasible once the emergency situation allows.

Question 76: Which type of submission may an IRB approve through expedited review?

Any study the sponsor requests to be fast-tracked
Initial review of a greater-than-minimal-risk drug trial
A study involving prisoners with more than minimal risk
Minor changes to previously approved research (Correct answer)

Correct answer: Minor changes to previously approved research

Expedited review covers minimal-risk research in listed categories and minor changes to approved research.

Question 77: The Declaration of Helsinki states that research involving human subjects may only proceed if:

The potential commercial value of results justifies the risk
The importance of the objective outweighs the risks and burdens to research subjects (Correct answer)
At least two IRBs in different countries have approved the protocol
The researcher has published at least five prior studies in the field

Correct answer: The importance of the objective outweighs the risks and burdens to research subjects

The Declaration of Helsinki requires that the importance of the research objective must outweigh inherent risks and burdens to participants.

Question 78: Which of the following is the proper way to make a correction to a CRF?

Add the initials of the person making the change, the date of the change, and , if necessary, a brief explanation of the change (Correct answer)
Completely blacken the incorrect entry and then enter the correct information
Initial using the initials of the sponsor's representative who reviewed the change
Back date the corrected entry with the date of the original entry

Correct answer: Add the initials of the person making the change, the date of the change, and , if necessary, a brief explanation of the change

When making corrections to a Case Report Form (CRF), the proper procedure is to draw a single line through the incorrect entry, ensuring the original entry remains legible. Then, the correct information should be written next to it, followed by the initials of the person making the change, the date of the change, and a brief explanation if necessary. This method maintains an audit trail and ensures data integrity.

Question 79: What is the purpose of a 'closeout' monitoring visit?

To ensure all trial activities are completed, documents are archived, and investigational product is reconciled (Correct answer)
To obtain final IRB approval for the study report
To transfer the master file to the FDA
To enroll the last subject into the study

Correct answer: To ensure all trial activities are completed, documents are archived, and investigational product is reconciled

A closeout visit confirms all data are clean, investigational product is accounted for, and the site can properly archive trial records.

Question 80: What is the timeframe for reporting unexpected fatal or life-threatening suspected adverse reactions to the FDA?

90 calendar days
7 calendar days (Correct answer)
15 calendar days
30 calendar days

Correct answer: 7 calendar days

Per 21 CFR 312.32, sponsors must report these within 7 calendar days.

Question 81: Which of the following is NOT a required element for full board IRB review approval?

Risks to subjects are minimized
Equitable selection of subjects
Informed consent will be sought from each subject
The sponsor has approved the protocol (Correct answer)

Correct answer: The sponsor has approved the protocol

Sponsor approval is not a regulatory criterion for IRB approval; IRBs evaluate ethical and safety criteria independently.

Question 82: How should an investigator prepare for a regulatory inspection?

Ensure documents are organized, complete, and accessible; review compliance and address known issues (Correct answer)
Destroy documents with errors
Refuse access
Only prepare the PI

Correct answer: Ensure documents are organized, complete, and accessible; review compliance and address known issues

Preparation includes organizing documents, ensuring staff readiness, reviewing compliance, and addressing known issues.

Question 83: Can an IRB suspend or terminate a trial?

Yes, for non-compliance or unexpected serious harm per 21 CFR 56.113 (Correct answer)
Only FDA can
IRBs can only recommend
Only the sponsor can

Correct answer: Yes, for non-compliance or unexpected serious harm per 21 CFR 56.113

Per 21 CFR 56.113, IRBs can suspend or terminate for non-compliance or unexpected serious harm.

Question 84: Which federal subpart specifically provides additional protections for prisoners as research subjects?

45 CFR 46 Subpart A (The Common Rule)
45 CFR 46 Subpart D
45 CFR 46 Subpart B
45 CFR 46 Subpart C (Correct answer)

Correct answer: 45 CFR 46 Subpart C

45 CFR 46 Subpart C specifically addresses additional protections for prisoners involved as research subjects.

Question 85: Under what limited circumstances may research involving human subjects proceed without prospective IRB review?

When the sponsor waives the requirement
When the PI certifies the research is safe
Emergency use of a test article under 21 CFR 50.23 and 56.104(c) when IRB review is not feasible (Correct answer)
When fewer than 10 subjects are enrolled

Correct answer: Emergency use of a test article under 21 CFR 50.23 and 56.104(c) when IRB review is not feasible

FDA regulations permit emergency use of an unapproved test article without prospective IRB approval when life-threatening situations exist and time is insufficient, but the IRB must be notified within 5 working days.

Question 86: When a child is capable of understanding the nature of a research study but has not yet reached the age of majority, what must occur IN ADDITION to obtaining parental or guardian permission?

The child's assent must be obtained (Correct answer)
The IRB must conduct a direct interview with the child
A second parent must co-sign the permission form
A court order must authorize the child's participation

Correct answer: The child's assent must be obtained

When children are capable of understanding, their assent — their affirmative agreement to participate — must be obtained in addition to parental or guardian permission. The IRB determines the appropriate assent process based on the child's age, maturity, and psychological state.

Question 87: Which essential document must be reviewed, signed, and dated by a subject (or legally authorized representative) before any study-specific screening procedure may be performed?

The Serious Adverse Event report form
The Informed Consent Form (ICF) (Correct answer)
The Case Report Form (CRF) demographic page
The Clinical Study Report signature page

Correct answer: The Informed Consent Form (ICF)

Obtaining a signed and dated ICF prior to any study-specific procedures is a fundamental ethical and regulatory requirement (ICH E6, 21 CFR Part 50). The CSR signature page is completed at trial end, SAE forms are used after enrollment, and CRF demographic pages capture data after consent is already obtained.

Question 88: Compared with a closed system, an open system under Part 11 requires additional controls such as:

Annual FDA inspection of the software
Removing audit trails
Paper backups of every record
Document encryption and appropriate digital signature standards (Correct answer)

Correct answer: Document encryption and appropriate digital signature standards

Section 11.30 requires open systems, where access is not controlled by the people responsible for the records, to add measures such as encryption and digital signature standards to protect authenticity, integrity, and confidentiality.

Question 89: When is re-consent required?

Never necessary
Only at completion
When significant new information arises that may affect willingness to continue (Correct answer)
Only for safety events

Correct answer: When significant new information arises that may affect willingness to continue

Required when new information could affect willingness, including safety findings, protocol amendments, or risk/benefit changes.

Question 90: Why must site-specific normal laboratory ranges (reference ranges) be collected and maintained in the Trial Master File?

They replace the need for a central laboratory manual when local labs are used
They allow the sponsor to convert local units to SI units in the clinical database
They enable accurate determination of whether laboratory results are clinically notable or constitute potential adverse events (Correct answer)
They fulfill the IRB's annual continuing-review data submission requirement

Correct answer: They enable accurate determination of whether laboratory results are clinically notable or constitute potential adverse events

Site-specific normal laboratory ranges are essential for contextualizing subject lab values: without knowing the local lab's reference intervals, neither investigators nor monitors can reliably classify a result as normal, abnormal-not-clinically-significant, or an adverse event. They do not replace lab manuals, serve unit conversion, or satisfy IRB reporting requirements.

Question 91: An investigational drug requires storage at 2–8°C. The site refrigerator maximum alarm was triggered over a weekend. What is the appropriate response?

Reset the alarm and continue using the IP
Use the IP within 24 hours to avoid waste
Document the excursion, quarantine affected IP, and contact the sponsor for disposition instructions (Correct answer)
Move the IP to a staff member's home refrigerator

Correct answer: Document the excursion, quarantine affected IP, and contact the sponsor for disposition instructions

Any temperature excursion must be documented and reported to the sponsor, and IP must be quarantined pending sponsor evaluation of product integrity.

Question 92: A subject was randomized into a study but was later found to have been ineligible due to a prohibited concomitant medication. The data monitor committee (DMC) is evaluating the study. This deviation should PRIMARILY be reported to:

The IRB, the sponsor, and documented in the regulatory binder (Correct answer)
The FDA directly by the site, bypassing the sponsor
No reporting is needed if the subject completed the study safely
Only the sponsor's data management team

Correct answer: The IRB, the sponsor, and documented in the regulatory binder

An enrollment eligibility deviation must be reported to the IRB as a protocol deviation and to the sponsor, and fully documented in the site's regulatory files.

Question 93: Under FDA regulations, who holds primary responsibility for ensuring that an IND is in effect before a Phase I study begins?

The contract research organization
The study sponsor (Correct answer)
The clinical investigator at each participating site
The IRB that approved the protocol

Correct answer: The study sponsor

The sponsor is responsible under 21 CFR 312.40 for ensuring an IND is in effect and that FDA has not placed the study on clinical hold before any investigation begins.

Question 94: What is 45CFR46?

HHS - Protection of Research Participants
FDA - Protection of Research Participants
DDS - Protection of Human Subjects
HHS - Protection of Human Subjects (Correct answer)

Correct answer: HHS - Protection of Human Subjects

45 CFR Part 46 is the Department of Health and Human Services (HHS) regulation titled 'Protection of Human Subjects.' This is often referred to as the 'Common Rule' and provides the foundational ethical framework for federally funded research involving human subjects. It outlines requirements for Institutional Review Boards (IRBs), informed consent, and protections for vulnerable populations.

Question 95: Which subpart of 45 CFR 46 provides additional protections for children involved in research?

Subpart C
Subpart D (Correct answer)
Subpart A
Subpart B

Correct answer: Subpart D

Subpart A is the Common Rule, Subpart B covers pregnant women, fetuses, and neonates, Subpart C covers prisoners, and Subpart D covers children.

Question 96: Which of the following must be submitted to the FDA to obtain an exemption to ship an unapproved drug across state lines for a clinical investigation?

A marketing application (NDA or BLA).
An Investigational New Drug Application (IND). (Correct answer)
A signed Form FDA 483.
An Institutional Review Board (IRB) approval letter.

Correct answer: An Investigational New Drug Application (IND).

An Investigational New Drug Application (IND) is the mechanism through which a sponsor requests an exemption from the federal law that prohibits the shipment of unapproved drugs in interstate commerce. The IND allows the lawful shipment of the investigational drug for the purpose of conducting clinical investigations.

Question 97: A subject in a blinded trial is hospitalized, and the treating physician requests the subject's treatment assignment for clinical management. The PI should:

Deny the request to protect trial integrity
Ask the sponsor's statistician for the randomization code
Follow the protocol's emergency unblinding procedure and document the unblinding event (Correct answer)
Provide the information verbally without documentation

Correct answer: Follow the protocol's emergency unblinding procedure and document the unblinding event

Emergency unblinding must follow the protocol-defined procedure, be documented in source records and the subject's file, and typically be reported to the sponsor promptly.

Question 98: Under what circumstances may a comparator drug (approved marketed product) be used as investigational product in a clinical trial?

Never; only experimental compounds qualify as IP
When the protocol designates it as a comparator and it is labeled and handled per GCP requirements (Correct answer)
When the PI obtains a separate IND for the comparator
Only if it has been reformulated by the sponsor

Correct answer: When the protocol designates it as a comparator and it is labeled and handled per GCP requirements

Approved drugs used as comparators in trials are considered IP and must be handled, labeled, stored, and documented per GCP even if commercially available.

Question 99: What is a pre-study (site qualification) visit?

An evaluation of whether a site has adequate facilities, personnel, and patient population (Correct answer)
A post-study visit
A financial meeting
A launch celebration

Correct answer: An evaluation of whether a site has adequate facilities, personnel, and patient population

This visit evaluates a site's suitability, assessing facilities, equipment, personnel, patient population, and GCP readiness.

Question 100: Full board review vs expedited review?

Full board requires quorum with discussion and vote; expedited allows chair to review minimal risk research (Correct answer)
Full board only for Phase III
No difference
Expedited is less thorough

Correct answer: Full board requires quorum with discussion and vote; expedited allows chair to review minimal risk research

Full board requires a convened meeting with quorum; expedited allows designated member(s) to review minimal risk research.

Question 101: What is the purpose of a Data Safety Monitoring Board (DSMB) and how does it relate to IRB oversight?

A DSMB is required only for device trials, not drug trials
A DSMB independently monitors accumulating safety and efficacy data and may recommend stopping a trial; the IRB remains the ethics overseer (Correct answer)
A DSMB replaces the IRB for Phase III trials and has authority to approve protocol changes
A DSMB and IRB are the same entity under a different name

Correct answer: A DSMB independently monitors accumulating safety and efficacy data and may recommend stopping a trial; the IRB remains the ethics overseer

DSMBs provide independent interim safety and efficacy monitoring, but the IRB retains independent ethical oversight authority and must receive DSMB reports as part of continuing review.

Question 102: A non-biometric electronic signature must use at least:

Two distinct identification components, such as a user ID and a password (Correct answer)
One component, such as a password
A handwritten signature scanned into the system
A fingerprint scan

Correct answer: Two distinct identification components, such as a user ID and a password

Section 11.200(a) requires non-biometric e-signatures to use at least two distinct identification components, such as an ID code and a password.

Question 103: What is Interactive Response Technology (IRT)?

Electronic health record
Automated system for randomization, drug assignment, supply management, and inventory tracking (Correct answer)
Only for AE reporting
Patient survey

Correct answer: Automated system for randomization, drug assignment, supply management, and inventory tracking

IRT automates randomization, treatment assignment, drug supply management, and inventory tracking.

Question 104: The FDA's Bioresearch Monitoring (BIMO) program inspects all of the following EXCEPT:

Sponsors and CROs
Health insurance companies processing subject claims (Correct answer)
IRBs and ethics committees
Clinical investigators

Correct answer: Health insurance companies processing subject claims

BIMO inspects clinical investigators, sponsors/CROs, IRBs, and in-vitro diagnostic manufacturers, but health insurers are not part of this program.

Question 105: A sponsor is implementing a risk-based monitoring approach for a large, multi-center trial. Which of the following best characterizes this strategy?

Requiring 100% source data verification for every participant at every site, regardless of site performance.
Eliminating all on-site monitoring visits in favor of remote data review only.
Assigning the responsibility of site monitoring entirely to the Institutional Review Board (IRB).
Focusing monitoring efforts on critical data and processes, with the intensity and frequency of monitoring tailored to sites identified as having higher risk. (Correct answer)

Correct answer: Focusing monitoring efforts on critical data and processes, with the intensity and frequency of monitoring tailored to sites identified as having higher risk.

Risk-based monitoring (RBM), as encouraged by ICH E6(R2), involves identifying and prioritizing risks to critical trial processes and data, then focusing monitoring activities on those areas of highest risk. [28, 19] It does not necessarily eliminate on-site visits but tailors the monitoring strategy based on risk factors. [19, 28]

Question 106: What is an FDA Warning Letter?

Drug approval letter
An official correspondence citing significant regulatory violations requiring prompt corrective action (Correct answer)
Successful inspection notification
Routine communication

Correct answer: An official correspondence citing significant regulatory violations requiring prompt corrective action

A Warning Letter identifies significant violations that may lead to enforcement action if not corrected.

Question 107: When investigational product (IP) is received at a clinical site, what is the FIRST action the site coordinator should take?

Notify the IRB of the IP receipt
Inspect the shipment and verify contents against the packing list and shipping manifest (Correct answer)
File the shipping documents without opening the package
Immediately dispense IP to enrolled subjects

Correct answer: Inspect the shipment and verify contents against the packing list and shipping manifest

Upon receipt, the site must inspect the shipment for integrity, verify contents against documentation, and check temperature monitoring devices before accepting the shipment.

Question 108: According to ICH E6, the investigator's brochure (IB) is provided to the investigator primarily to:

Serve as the protocol for the trial
Satisfy regulatory filing requirements for the site
Provide clinical and nonclinical data to support the safe use of the investigational product (Correct answer)
Document the investigator's product training

Correct answer: Provide clinical and nonclinical data to support the safe use of the investigational product

The IB compiles relevant clinical and nonclinical information to help investigators understand and manage risks associated with the investigational product.

Question 109: What is the significance of a delegation log?

Documents all individuals authorized to perform study-specific tasks and their responsibilities (Correct answer)
Records financial transactions
Tracks participant visits only
Only for Phase I

Correct answer: Documents all individuals authorized to perform study-specific tasks and their responsibilities

The delegation log lists all persons delegated trial-related duties, their tasks, and training documentation.

Question 110: What is SDV's role in data quality?

Only at trial end
Only checks demographics
Optional and rarely performed
Comparing CRF data against source documents to confirm accuracy, completeness, and consistency (Correct answer)

Correct answer: Comparing CRF data against source documents to confirm accuracy, completeness, and consistency

SDV involves monitors comparing CRF entries against original source documents.

Question 111: What must the IRB consider when reviewing a protocol?

Only the statistical plan
Protocol, consent, investigator qualifications, recruitment, risk/benefit assessment, and participant protections (Correct answer)
Only budget and timeline
Only manufacturer info

Correct answer: Protocol, consent, investigator qualifications, recruitment, risk/benefit assessment, and participant protections

The IRB must review the complete protocol, consent, qualifications, recruitment, risk/benefit, and monitoring plans.

Question 112: Which ALCOA principle requires that data be recorded at the time the observation is made?

Original
Accurate
Legible
Contemporaneous (Correct answer)

Correct answer: Contemporaneous

Contemporaneous means data must be recorded at the time the observation occurs, not reconstructed later from memory.

Question 113: A sponsor requires that leftover IP be destroyed on-site. Which document must be completed to support this?

Adverse Event Report
Source document amendment
IP Destruction Record / Certificate of Destruction (Correct answer)
Investigator Agreement

Correct answer: IP Destruction Record / Certificate of Destruction

A destruction record or certificate of destruction, signed by authorized site personnel, is required to document method, date, and quantity of IP destroyed on-site.

Question 114: How is a 'certified copy' of a source document defined under ICH E6 GCP?

A verified copy confirmed to be an exact reproduction of the original, preserving all content and context (Correct answer)
A document notarized by a legal authority confirming the investigator's signature is authentic
A digital scan uploaded to a validated electronic document management system
A photocopy reviewed and stamped by the principal investigator as accurate

Correct answer: A verified copy confirmed to be an exact reproduction of the original, preserving all content and context

A certified copy is any copy — paper, microfilm, or electronic — that has been verified to contain all the same information as the original, including data describing its context, content, and structure. Verification confirms the copy is a true and complete reproduction.

Question 115: What authority does an IRB have when it determines that unanticipated problems pose serious risks to participants or others?

The IRB may only recommend modifications; only the sponsor can halt the study
The IRB must defer to the FDA before taking any enforcement action
The IRB has the authority to suspend or terminate approval of research that is not being conducted in accordance with its requirements (Correct answer)
The IRB can issue a warning letter but must allow the study to continue until federal review

Correct answer: The IRB has the authority to suspend or terminate approval of research that is not being conducted in accordance with its requirements

Per 45 CFR 46.113, an IRB has the authority to suspend or terminate approval of research that is not being conducted in accordance with the IRB's requirements or that has been associated with unexpected serious harm to participants. This is a core institutional safeguard.

Question 116: Which type of study is typically conducted after a product has received marketing approval?

Phase I
Phase IV (Correct answer)
Phase III
Phase II

Correct answer: Phase IV

Phase IV (post-marketing) studies look at long-term safety, rare adverse events, new populations, or additional uses after approval.

Question 117: In the context of ICH GCP, what is the purpose of the Trial Master File (TMF)?

To collect adverse event data for regulatory submission
To contain essential documents that allow evaluation of trial conduct and data quality (Correct answer)
To document the sponsor's financial agreements with investigators
To serve as the final clinical study report submitted to health authorities

Correct answer: To contain essential documents that allow evaluation of trial conduct and data quality

The TMF holds essential documents that individually and collectively permit evaluation of the conduct of the trial and the quality of the data produced.

Question 118: When an IRB reviews research involving prisoners under Subpart C, which membership requirement applies?

A physician must chair the IRB
At least one member must be a prisoner or a prisoner representative (Correct answer)
All members must be employed by the prison
No special membership requirement applies

Correct answer: At least one member must be a prisoner or a prisoner representative

45 CFR 46.304 requires at least one IRB member to be a prisoner or a prisoner representative with appropriate background. A majority of members, excluding prisoner members, must have no association with the prison.

Question 119: Which scenario represents a violation of the 'Attributable' ALCOA principle?

A CRC documents their own initials on a delegated task
A nurse signs their initials next to a recorded vital sign
A data entry clerk enters data under another staff member's login credentials (Correct answer)
A PI dates and signs the protocol signature page

Correct answer: A data entry clerk enters data under another staff member's login credentials

Using another person's login credentials violates attributability because the data cannot be traced to the person who actually performed or recorded it.

Question 120: An investigator receives a sponsor safety letter reporting a new SAE from a different site using the same investigational drug. What is the investigator's primary obligation?

Discard the letter as it pertains to another site
Notify the IRB/IEC and assess implications for subjects currently enrolled at their site (Correct answer)
File an independent report directly to the FDA
Immediately withdraw all enrolled subjects from the trial

Correct answer: Notify the IRB/IEC and assess implications for subjects currently enrolled at their site

Investigators must forward relevant safety information to their IRB/IEC and consider whether the new safety data changes the risk-benefit assessment for subjects at their own site.

Question 121: What responsibilities exist regarding scientific misconduct?

Only relevant if affecting results
No responsibility to report
Only sponsor responsibility
Researchers must maintain integrity and report observed misconduct through institutional channels (Correct answer)

Correct answer: Researchers must maintain integrity and report observed misconduct through institutional channels

Researchers have ethical and regulatory obligations to conduct research with integrity and report suspected misconduct.

Question 122: A subject's Week 8 visit happens 2 days outside the protocol window, with no impact on safety or key endpoints. How is this usually handled?

The visit date in the CRF is corrected to fall within the window
The subject is withdrawn from the study
Reported to FDA within 24 hours as a serious violation
Documented as a minor deviation and reported per sponsor and IRB policy (Correct answer)

Correct answer: Documented as a minor deviation and reported per sponsor and IRB policy

Window deviations with no safety or data-integrity impact are usually minor and are documented and reported according to sponsor and IRB requirements.

Question 123: During a monitoring visit, the CRA finds that the investigator's brochure (IB) version in the regulatory binder is two versions old. What should the CRA do?

Note it as a protocol deviation and file it in the monitoring log
Accept it because older versions are still valid references
Immediately halt subject dosing until the binder is updated
Provide the current IB version, document the finding, and ensure the IRB receives the updated version (Correct answer)

Correct answer: Provide the current IB version, document the finding, and ensure the IRB receives the updated version

The CRA should supply the current IB, document the discrepancy as a finding, and confirm the IRB has approved the updated version as required.

Question 124: What is the minimum number of IRB members?

10
3
5 (Correct answer)
6

Correct answer: 5

According to FDA regulations (21 CFR 56.107), an Institutional Review Board (IRB) must have at least five members. This minimum number ensures a diverse range of expertise and perspectives are present during the review of research protocols. A larger, diverse committee helps to provide a thorough and unbiased ethical and scientific review of studies involving human subjects.

Question 125: Which form is used in the United States for mandatory reporting of serious adverse events by investigators and manufacturers to the FDA?

MedWatch Form 3500A (Correct answer)
CIOMS I Form
FDA Form 1572
ICH E2B Individual Case Safety Report

Correct answer: MedWatch Form 3500A

The MedWatch Form 3500A is the FDA's mandatory reporting form for healthcare professionals, manufacturers, and distributors to report serious adverse events. The CIOMS I form is used for international submissions, FDA Form 1572 is the investigator statement of responsibilities, and ICH E2B is an electronic transmission standard.

Question 126: Which population requires additional regulatory protections beyond the standard informed consent process under Subpart D of the Common Rule?

Prisoners enrolled in studies examining conditions affecting the prison population (Correct answer)
Adults with limited English proficiency
Children enrolled in minimal-risk survey research
Healthy adult volunteers in phase I pharmacokinetic studies

Correct answer: Prisoners enrolled in studies examining conditions affecting the prison population

Subpart C of 45 CFR 46 establishes additional protections for prisoners because their voluntariness may be compromised by their circumstances. Subpart D covers children. Adults with limited English proficiency require translated documents but are not a separately regulated vulnerable subgroup under Subpart C or D.

Question 127: Who is ultimately responsible for ensuring that investigational product at a clinical site is handled, stored, and dispensed in accordance with the protocol?

The site's IRB or ethics committee
The hospital pharmacy director
The sponsor's clinical research associate (CRA)
The principal investigator (PI) (Correct answer)

Correct answer: The principal investigator (PI)

Under ICH E6 GCP, the principal investigator bears ultimate responsibility for all investigational product management at the site, including storage, dispensing, and record-keeping. The PI may delegate specific tasks to qualified staff, but accountability cannot be delegated away.

Question 128: What is a placebo in clinical research?

A type of adverse event
An inactive substance or treatment used as a comparator (Correct answer)
The standard of care treatment
A higher dose of the investigational drug

Correct answer: An inactive substance or treatment used as a comparator

A placebo is an inactive substance designed to resemble the investigational product but contains no active therapeutic ingredients.

Question 129: When must an investigator obtain re-consent from a study subject?

Re-consent is never required once initial consent is obtained
When there is a protocol amendment that materially affects subject risk or willingness to participate (Correct answer)
Only when the study sponsor requests it
Only when the IRB conducts a continuing review

Correct answer: When there is a protocol amendment that materially affects subject risk or willingness to participate

Re-consent is required when protocol changes or new information significantly impact subject risk or could affect a subject's decision to continue participating.

Question 130: A subject in a trial for an investigational antidepressant reports developing a mild rash two weeks after starting the drug. The subject has a known history of seasonal allergies and recently started using a new laundry detergent. In assessing this adverse event, what is the MOST critical determination the investigator must make for safety reporting purposes?

The exact date the new laundry detergent was first used.
The likelihood that the event is related to the investigational product (causality). (Correct answer)
Whether the event meets the criteria for 'serious.'
If the event needs to be reported to the FDA via MedWatch by the site.

Correct answer: The likelihood that the event is related to the investigational product (causality).

The investigator's assessment of causality (i.e., whether there is a reasonable possibility that the drug caused the event) is critical. This determination transforms an 'adverse event' into a 'suspected adverse reaction', which is the basis for expedited safety reporting by the sponsor to the FDA. While seriousness is also important, causality is the key factor that links the event to the drug for regulatory reporting.

SOCRA CCRP — Certified Clinical Research Professional

The SOCRA CCRP exam is a 130-question certification assessment for clinical research professionals, covering U.S. federal regulations, ICH Good Clinical Practice guidelines, and ethical principles across the full clinical trial lifecycle.

130

Questions

240 min

Time Limit

71%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds